Concepedia

Xiaodong Zhang

XZ

Statistics

Publications

14

Citations

1.1K

H-Index

12

Active since

2009

Affiliations

Peking University(Current)

Peking University Cancer Hospital

Tianjin Medical University Cancer Institute and Hospital

First Affiliated Hospital of Zhengzhou University

First Affiliated Hospital of Anhui Medical University

Xiaodong Zhang is an author at Peking University specializing in oncology, medicine, and esophageal cancer pharmacotherapy.

ORCID

Publications per year

2009–2024

14

Publications

14

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Jin Lü, Yuxian Bai, Teng Mao et al. · JAMA · 2021 · 801 citations · Full text

, , +17

ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).

Rui‐Hua Xu, Jin Lü, Yuxian Bai et al. · Journal of Clinical Oncology · 2021 · 63 citations

, , +16

Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase <scp>II</scp> trial

Ming Lu, Xicheng Wang, Lin Shen et al. · Cancer Science · 2016 · 47 citations · Full text

, , +11

Detection of gastric carcinoma‐associated MG7‐Ag by serum immuno‐PCR assay in a high‐risk Chinese population, with implication for screening

Lian Zhang, Jun Ren, Kai‐Feng Pan et al. · International Journal of Cancer · 2009 · 45 citations · Full text

, , +12

Programmed death‐ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor

Wencheng Zhang, Qingsong Pang, Xiaodong Zhang et al. · Cancer Science · 2017 · 45 citations · Full text

, , +16

1–5 of 14